Personal Genome Diagnostics will use its funding to expand its liquid biopsy portfolio. Cleveland Diagnostics plans to develop early detection tests for lung and breast cancer.
Two diagnostics companies announced they will be able to advance their cancer portfolio with new funding. Baltimore-based Personal Genome Diagnostics Inc. announced it raised $103m in a series C financing round and Cleveland Diagnostics announced it raised $17.4m in a series D round.
Personal Genome Diagnostics announced on 10 February it raised $103m in a new round of financing.
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
